Alexion Pharmaceuticals, Inc. (ALXN) Tops Q1 EPS by 4c; Boosts Outlook

April 25, 2013 6:35 AM EDT
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported Q1 EPS of $0.65, $0.04 better than the analyst estimate of $0.61. Revenue for the quarter came in at $338.9 million versus the consensus estimate of $336.56 million.

Alexion Pharmaceuticals, Inc. sees FY2013 EPS of $2.87-2.97, versus prior guidance of $2.82-2.92 and the consensus of $2.90. Alexion Pharmaceuticals, Inc. sees FY2013 revenue of $1.505-1.520 billion, versus prior guidance of $1.490-1.505 billion and the consensus of $1.51 billion.

For earnings history and earnings-related data on Alexion Pharmaceuticals, Inc. (ALXN) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance, Hot Guidance

Related Entities

Earnings